0

Treatment of Cardiac Tamponade

Click below to access your content. Once you have successfully completed this course your certificate will become available at the top of this page and on your My Certificates page.

Course Details

Credit/contact hours: .5
Estimated time to complete: 30 minutes
Publication Date: March 14, 2019
Expiration date: March 14, 2022
Reviewed:

Description:

In patients with a diagnosis of pericardial effusion, especially when accompanied by symptoms or signs of cardiac tamponade, a number of therapeutic interventions are possible. These include emergency stabilization with hydration, avoidance of vasodilators, and potentially pressors. Pericardiocentesis, surgical pericardial windowing, or percutaneous balloon pericardiotomy are potential therapies.

You Will Learn

  • To distinguish early emergency therapy for cardiac tamponade from more definitive therapies
  • To describe the techniques for pericardiocentesis in the cardiac catheterization laboratory
  • To summarize surgical therapies for cardiac tamponade and/or recurrent pericardial effusions
  • To review the analysis of fluid removed during treatment of pericardial effusions

Method and medium:

Learners participate in the interactive learning modules by correctly answering multiple choice questions dispersed throughout. Learners will be prompted to try again if a question is answered incorrectly.The course will open in a new tab - to exit the course, simply close that tab.

Michael Ragosta III, MD

Dr. Michael Ragosta is an attending cardiologist at the University of Virginia Health System with a sub-specialty in interventional cardiology. His clinical practice includes complex percutaneous coronary intervention, myocardial infarction, valvular heart disease, structural heart disease, and general cardiology. Dr. Ragosta is the Director of the Cardiac Catheterization Laboratories at UVA and author of numerous textbooks related to cardiac catheterization and hemodynamic interpretation.

DISCLOSURE: This individual reports no relevant financial relationships with commercial entities.

Please rate this


 5/5 (6)